havas glp-1 Curious about how GLP-1s are reshaping industries across markets? , Hear what Loris Repellin, Chief of Staff to the Global CEO, Health & Creative Networks, has to say about why adapting to this HAVAS HOSTS "GLP101 DAY," CONNECTING

It validates your doctor concern while redirecting the conversation back to evidence

We expected that patients taking the GLP-1s for obesity may have a lower cost of care and improved medical outcomes as we presumed that the weight loss could have led to a decrease in the frequency of office/hospital visits and/or the use of drugs for treatment of conditions such as hypertension, high cholesterol and osteoarthritis

Addressing underlying hormonal imbalances alongside Retatrutide treatment can enhance outcomes

Because of its triple-action mechanism, it appears to have a broader metabolic impact compared with traditional GLP-1 agonists like Wegovy and Mounjaro

Recent literature is cited on patients undergoing upper endoscopy with no predictability regarding holding the drug and finding retained gastric contents

Many psychiatric medications cause significant weight gain